An Economic Evaluation of Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting.
|20/01/2010||March 2010||Reimbursement not Recommended|
Alexion Pharma UK. Ltd have failed to demonstrate the cost-effectiveness of eculizumab (Soliris®) for the treatment of PNH in the Irish healthcare setting.
|15/07/2013||14/10/2013||Reimbursement not Recommended|
The NCPE do not believe that eculizumab (Soliris®) is value for money for the treatment of patients with PNH in the Irish Healthcare setting